San Donato Hospital
Leukemia treatment cost in Italy typically depends on the diagnostic approach and therapy type, with a Bone marrow biopsy running from Price on request to Price on request . Primary treatments like Leukemia chemotherapy often range from Price on request to Price on request , while advanced CAR T-cell therapy costs from Price on request to Price on request . Expenses vary based on disease stage and hospital stay duration, typically offering 20-40% savings compared to the US. Top treatment centers are located in Milan.
Typical Leukemia Treatment Costs in Italy
Bookimed Expert Insight: Patients with complex hematological conditions benefit from integrated research and clinical care at IRCCS-accredited centers. Professor Fabio Ciceri at San Raffaele specializes in advanced cell and gene therapy clinical trials for leukemia. This center is ideal for patients seeking the world's first stem cell therapies or bone marrow transplantation. The facility manages over 52,000 operations annually, providing high-volume expertise for high-risk cases.
No hidden fees – just official clinic prices. Pay at the clinic for Leukemia treatment and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Leukemia treatment and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Leukemia treatment journey.
Dr. Fabio Ciceri heads the Hematology and Bone Marrow Transplantation Unit at San Raffaele Research Hospital. He is a primary investigator in clinical trials for cell and gene therapies. These trials treat hematological cancers, immune deficiencies, and neuromuscular disorders. Dr. Ciceri works at San Raffaele, the hospital that achieved the world's first stem cell therapy for ADA-SCID.
Written by Anna Leonova
Italy hosts globally recognized leukemia centers like San Raffaele Research Hospital in Milan. These facilities hold IRCCS accreditation from the Italian Ministry of Health. They integrate high-volume clinical care with advanced hematology research to provide innovative stem cell therapies and CAR T-cell treatments.
Bookimed Expert Insight: San Raffaele stands out because it operates one of Europe's largest research hospitals. They performed the world’s first stem cell therapy for rare immune disorders. Our data shows it serves 300,000 patients yearly. This massive volume ensures doctors like Dr. Fabio Ciceri maintain unmatched expertise in complex blood disorders.
Patient Consensus: Patients emphasize that northern centers like San Raffaele offer the easiest access to experimental trials. One patient noted that getting a second opinion at these top clinics helped correct a previous misdiagnosis of leukemia.
Italy offers advanced hematology treatments including CAR T-cell therapy and specialized stem cell transplants. Research centers like San Raffaele utilize gene therapy and molecular diagnostics. Highly trained specialists treat complex leukemia cases within JCI or IRCCS-accredited research hospitals in Milan and Pavia.
Bookimed Expert Insight: Italian research hospitals serve over 300,000 patients yearly while maintaining IRCCS status. This designation confirms they combine direct clinical care with active research. Dr. Fabio Ciceri at San Raffaele has published over 180 papers on hematological cancers. This deep academic focus often grants patients earlier access to experimental protocols.
Patient Consensus: Patients note that CAR-T therapy has led to long-term remission when chemotherapy failed. Many emphasize that getting specialized second opinions in Milan can quickly clarify initial diagnosis errors.
Italy hosts globally recognized leukemia specialists within IRCCS-accredited research hospitals. These experts lead advancements in allogeneic transplants and gene therapies. Top hematologists practice in Milan and Rome. They hold prestigious leadership roles in European oncology networks and clinical trial groups.
Bookimed Expert Insight: Data shows that San Raffaele performs over 52,000 operations annually and holds a unique IRCCS status. This designation means the clinic must combine patient care with active research. For leukemia patients, this provides direct access to the world’s first licensed stem cell therapies not found in standard hospitals.
Patient Consensus: Patients note that top Italian specialists often resolve complex misdiagnoses through advanced blood analysis. They emphasize traveling directly to high-volume centers in Milan for the highest level of competence.
During your first leukemia appointment in Italy, ask about personalized protocols like European LeukemiaNet guidelines and CAR T-cell therapy eligibility. Clarify timelines for bone marrow biopsies and specialized diagnostic tests. Confirm how doctors manage side effects and infections within the IRCCS-accredited research hospital framework.
Bookimed Expert Insight: Italian IRCCS-accredited centers like San Raffaele combine clinical care with high-level research. These institutions perform over 52,000 operations annually and offer unique therapies, such as the world's first ADA-SCID stem cell treatment. If you are seeking advanced cell or gene therapy, prioritize hospitals with this dual research-clinical designation for the best access to experimental protocols.
Patient Consensus: Patients note that some initial consultations can feel brief, so it is vital to bring a translated list of questions and request a written summary. Many recommend confirming if the hospital provides interpreters or if a private one is needed for complex medical discussions.
Italy offers a full range of leukaemia treatments through specialised research hospitals. Patients access options including CAR T-cell therapy and targeted drugs like tyrosine kinase inhibitors. They also offer allogeneic stem cell transplants. Major Milanese centres combine clinical research with intensive care for acute and chronic leukaemia cases.
Bookimed Expert Insight: Italian research hospitals often hold IRCCS accreditation from the Ministry of Health. This status confirms they combine patient care with active medical research. San Raffaele, for instance, has published 180 scientific papers. It also handles 300,000 patients annually. This research focus gives patients earlier access to experimental protocols before they become standard elsewhere.
Patient Consensus: Patients note that Italian specialists frequently use precise diagnostics to check cases from other regions. They emphasise the importance of having on-site transplant units and supportive care teams. These teams help manage infections during intensive chemotherapy cycles in Italy.
San Raffaele and San Donato Hospital in Milan are top choices for leukaemia treatment in Italy. These centres hold Ministry of Health (IRCCS) accreditation. They specialise in bone marrow transplantation, immunotherapy, and stem cell therapies. Leading haematologists like Dr Fabio Ciceri manage complex blood cancer cases here.
Bookimed Expert Insight: Milan is the primary hub for this treatment. Patients often choose San Raffaele for its focus on clinical trials. Dr Fabio Ciceri has published over 180 papers. He acts as a principal investigator for gene therapy trials. This provides access to new leukaemia treatments often unavailable elsewhere in Europe.
Patient Consensus: Patients find that university hospitals in Italy offer more expertise than general private clinics. Experience suggests these centres resolve misdiagnoses quickly. They use precise blood analysis and bone marrow biopsies in Milan.
Italy offers active clinical trials for leukaemia through prestigious research hospitals. These centres conduct early-phase studies for AML, ALL, and CML subtypes. High-volume facilities in Milan and Rome lead Europe in non-profit phase 1 cancer trials. Patients can access cell and gene therapy protocols for refractory cases.
Bookimed Expert Insight: Italian research hospitals like San Raffaele handle over 300,000 patients annually. This massive volume drives their clinical trial capacity. A lead investigator like Dr Fabio Ciceri at San Raffaele holds memberships in over 9 international blood and marrow groups. This connectivity often gives patients early access to emerging European protocols long before they reach general clinical use.
Patient Consensus: Patients note the high competence of Italian specialists. They suggest confirming trial eligibility for international participants. Many find that comprehensive blood analysis in Italy often clarifies complex diagnoses. Those visiting Italy appreciate the coordinated support during their appointments.
Leukaemia treatment in Italy begins immediately or within days for acute cases. Italian medical protocols treat acute leukaemia as a medical emergency. Patients often receive admission on the same day as diagnosis. Induction chemotherapy typically starts within 24 to 72 hours to manage rapidly dividing cells.
Bookimed Expert Insight: Acute cases get immediate priority. Italian research hospitals like San Raffaele blend urgent clinical care with academic research. Data shows these centres manage 300,000+ patients annually. This high volume allows doctors to fast-track complex cases involving rare mutations. These often require specialised gene or cell therapies. Dr Fabio Ciceri, for example, has published over 180 papers on haematological cancers.
Patient Consensus: Patients mention that Italian specialists quickly rule out misdiagnoses through high-precision blood and marrow analyses. This provides reassurance before starting intensive treatments.
English is common among senior doctors and consultants within major Italian research hospitals, especially in Milan. Specialists often attend international conferences and publish in English. However, language consistency varies among nursing, administrative, and support staff who manage daily care.
Bookimed Expert Insight: While doctors at centres like San Raffaele treat 300,000+ patients annually, leukaemia patients should prioritise facilities with IRCCS accreditation. This status marks Italy's top research hospitals. These centres usually have more English-proficient specialists. This is because they lead global clinical trials for CAR T-cell therapy.
Patient Consensus: Patients note that major Milan hospitals operate at the highest level. They suggest bringing translated medical summaries. Even competent specialists appreciate having clear, written English documentation for complex leukaemia diagnoses.